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ABSTRACT
Background and Aims Indirect estimationmethods are required for estimating the size of populationswhere only a pro-
portion of individuals are observed directly, such as problem drug users (PDUs). Capture–recapture andmultiplier methods
are widely used, but have been criticized as subject to bias. We propose a new approach to estimating prevalence of PDU
from numbers of fatal drug-related poisonings (fDRPs) using linked databases, addressing the key limitations of simplistic
‘mortality multipliers’. Methods Our approach requires linkage of data on a large cohort of known PDUs to mortality
registers and summary information concerning additional fDRPs observed outside this cohort. We model fDRP rates
among the cohort and assume that rates in unobserved PDUs are equal to rates in the cohort during periods out of treat-
ment. Prevalence is estimated in a Bayesian statistical framework, in which we simultaneously fit regression models to
fDRP rates and prevalence, allowing both to vary by demographic factors and the former also by treatment status.
Results We report a case study analysis, estimating the prevalence of opioid dependence in England in 2008/09, by gen-
der, age group and geographical region. Overall prevalence was estimated as 0.82% (95% credible interval = 0.74–0.94%)
of 15–64-year-olds, which is similar to a published estimate based on capture–recapture analysis. Conclusions Our
modelling approach estimates prevalence from drug-related mortality data, while addressing the main limitations of sim-
plistic multipliers. This offers an alternative approach for the common situation where available data sources do not meet
the strong assumptions required for valid capture–recapture estimation. In a case study analysis, prevalence estimates
based on our approach were surprisingly similar to existing capture–recapture estimates but, we argue, are based on a
much more objective and justifiable modelling approach.
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INTRODUCTION
Information on the size of the injecting and opioid-using
population globally is increasingly important to support
and motivate public health strategies to eliminate hepatitis
C virus (HCV) [1–5], reverse upward trends in opioid over-
dose deaths [6,7] andmonitor treatment provision [7,8]. It
is well known that population surveys seriously underesti-
mate the prevalence of problem drug use—although they
can contribute information in other ways [9,10]. Instead,
‘indirect’ methods are recommended, such as capture–
recapture and multipliers. Addiction has previously
highlighted the growing dissatisfaction with the quality
and transparency in the evidence base on the prevalence
of opioid use and injecting [11].
There are discrepancies in global estimates of the prev-
alence of injecting and other problem drug use, as well as
inconsistencies in and controversies concerning national
and city-level estimates. For instance, it is unclear what is
the original method or source data for US estimates
[8,12–14]. Recent estimates in Australia were acknowl-
edged to be potentially biased andwere challenged by other
researchers [15–18]. National estimates of injecting drug
use were found to be inconsistent with information on
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HCV morbidity in England, and discrepant estimates have
been generated in both Scotland and England based on
the same source data [1,19–22].
Indirect methods of prevalence estimation rely upon as-
sumptions that are often violated, and can be impossible to
validate in any given data set. Broadly speaking, the valid-
ity of capture–recapture analysis is questionable when the
dependence structure between the data sources used is
complex, and when the target population is heterogeneous
in behaviour [23,24]. In this situation, it can be impossible
to distinguish between a range of models with similar or
identical fit whichmay, however, give widely different prev-
alence estimates. See Box 1 for more detail and a case
study.
Box 1. Difficulties with capture–recapture estimation:
case study of annual estimation in England
Capture–recapture analysis involves modelling the
overlap between lists of individuals in contact with
K services or bodies, usually using log-linear regres-
sion. The pattern of overlap is extrapolated to esti-
mate the missing cell count—the number of
individuals from the target population who were
not observed in any of the data sources—and hence
the prevalence. Although some level of dependencies
between data sources can be accounted for by in-
cluding interaction terms in the model, a key as-
sumption is made that there is no K-way
interaction. This has been described as an ‘act of
faith’ and is impossible to verify from the data [38].
Caution about the validity of capture–recapture-
based estimates is advised in particular if the ‘satu-
rated model’ (a model that includes the maximum
possible number of interaction terms) has the best
fit after penalizing for model complexity [30]. When
this is the case, alternative models with the same
number of parameters and identical ‘fit’ can provide
widely different prevalence estimates [23].
In practice, there are usually multiple potential
sources of dependencies and heterogeneity in data
sources used for capture–recapture. In particular,
we have shown that cross-referral of individuals be-
tween drug treatment and other services—which
may be a sign of a more developed approach to ad-
dressing opioid disorders—creates a complex depen-
dence structure and potential bias [23]. For
example, in England, official annual estimates of the
number of opioid and problem drug users are based
on capture–recapture analysis of the overlap between
four data sources: ‘treatment’, ‘arrest for possession’,
‘probation’ and ‘prison’ [39,40]. The anticipated de-
pendence structure between these is very complex,
in particular due to direct referrals between the three
criminal justice system sources and from any of these
into treatment [23].
Given this complexity, it is not surprising that inclusion
of multiple three-way interaction terms between data
sources (e.g. the saturated model) is required to obtain
adequate model fit, and that the possibility of a
four-way interaction cannot be excluded. For example,
we found this to be the case in a re-analysis of the prob-
lem drug use data set from 2009/10 [41]. Estimates
from a number of models with the same fit were highly
variable and unrealistically high, ranging from 2.1 to
6.6% of the population aged 15–64 years. See
Supporting information, Appendix A for more detail.
This is in stark contrast to the official estimate from
the sameyear: 0.89% (95%confidence interval=0.87–
0.92%) [41]. However, these annual estimates are de-
pendent upon a number of unjustified decisions made
in the model-fitting procedure. In particular, the ana-
lysts only allow a maximum of two (two-way) interac-
tion terms, regardless of model fit statistics and despite
the complex dependence structure described above.
Three-way interaction terms are not considered. There
is no theoretical basis for this rule, although it has been
noted that researchersmight ‘try to avoid fitting the sat-
urated model’ because it often produces higher preva-
lence estimates [42]. Other authors have also
demonstrated a tendency for capture–recapture models
including higher order interactions to produce higher,
and often extremely variable, prevalence estimates [43].
In the annual estimation exercise in England, subjective
judgements are also made to replace any estimates not
deemed to be ‘credible’with estimates based on an alter-
native method [39]. We further note that analyses are
stratified by local area and, in some areas, also by age
group and gender, which reduces statistical power to de-
tect dependencies between data sources. Prevalence esti-
mates by local area, age group and gender are important
for planning purposes, but a statistically more powerful
approach is to generate these from a single regression
model with covariates [44].
Multiplier methods are a simple and widely used alter-
native [25–31]. Estimation of the size of the target popula-
tion (N) requires a ‘benchmark’ (d)—the number of
individuals from the target population that are detected
via some source—and an estimate of the proportion of
the target population that we would expect to detect in this
way (p); N is then estimated by d/p, where 1/p is often re-
ferred to as the ‘multiplier’. For example, dividing the num-
ber of fatal drug-related poisonings (fDRPs) among
problem drug users (PDUs) over a year by an estimate of
the proportion of PDUswho die such a death in 1 year gives
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an estimate of the number of PDUs. The approach has its
basis in sampling theory and can be described more gener-
ally as inverse probability weighting, or a simplified special
case of the back-calculation approach [32]. It is strongly
related to the case of a two-sample capture–recapture anal-
ysis and generally viewed as inferior to multiple source
(three or more sources) capture–recapture. Where a ‘per-
fect’ multiplier is not available, pragmatism may favour a
multiplier that is neither specific to the benchmark popula-
tion nor year to which it is being applied [13,15,33–34],
which can dramatically affect the population estimate
[35–37]. It is difficult to then judge the validity of the
resulting population size estimates.
In this paper we revisit the idea of estimating preva-
lence from drug-related mortality data. We propose a
newmethodological approach within a Bayesian statistical
framework, addressing the most common criticisms of tra-
ditional ‘multiplier’ approaches.
LIMITATIONS OF TRADITIONAL
MULTIPLIER METHODS
We first describe several common criticisms of multiplier
methods, which we aim to address with our proposed ap-
proach. We focus on mortality multipliers in this text, but
the same general criticisms apply to other types of multi-
pliers, e.g. treatment multipliers.
(i) Bias due to borrowing multipliers across settings: to be
unbiased, the multiplier needs to be estimated from a
representative and contemporaneous sample of the
target population. Rates of events such as fDRP can
be expected to vary across locations and over time,
such that ‘borrowing’ multipliers across settings will
not often be valid. Further, different studies may use
different working definitions of fDRP.
(ii) Failure to account for heterogeneity in the multiplier: even
within the time-period and location of interest, fDRP
rates are known to vary by age group and gender
[45–47], with the two factors probably interacting
[22] and, importantly, to vary by drug treatment sta-
tus [24,48,49]. Traditional multiplier exercises have
ignored such heterogeneity.
(iii) Inappropriate case definitions: multiplier approaches as-
sume that all individuals in the ‘benchmark’ were
among the target population. This can be difficult to
establish in practice. For example, not all fDRP deaths
occur among PDUs. Further, it is crucial that the same
case definition (e.g. of fDRP) is used to derive both the
benchmark and the multiplier.
(iv) Failure to adequately account for uncertainty: there are
two sources of statistical uncertainty: sample uncer-
tainty in the benchmark, d, and uncertainty around
themultiplier. Both should be accounted for in the cal-
culation of an appropriate confidence or credible inter-
val (CrI) around the prevalence estimate. Where
Table 1 Summary data by financial year and demographic group for fatal drug-related poisonings (fDRPs) and person-years at risk while
on and off treatment in the Drug Data Warehouse (DDW), plus fDRPs not linked to the DDW (dmiss) and total known opioid dependent
people (nDDW). Data are aggregated across regions for display purposes only.
Year Group
On treatment Off treatment
Unobserved
fDRPs
(dmiss)
Observed
opioid-
dependent
people
(nDDW)
fDRPs
(dDDW)
Person-
years
Rate/
1000
fDRPs
(dDDW)
Person-
years
Rate/
1000
2005/06 Males < 35 55 32454 1.69 42 12160 3.45
Males 35–64 35 24155 1.45 42 5945 7.07
Females < 35 14 15506 0.90 5 4016 1.25
Females 35–64 9 8524 1.06 8 1643 4.87
2006/07 Males < 35 50 36073 1.39 33 14389 2.29
Males 35–64 39 30133 1.29 39 7988 4.88
Females < 35 10 17223 0.58 7 4507 1.55
Females 35–64 9 10484 0.86 8 2122 3.77
2007/08 Males < 35 45 38004 1.18 35 16999 2.06
Males 35–64 72 36063 2.00 32 10042 3.19
Females < 35 11 18113 0.61 5 4750 1.05
Females 35–64 16 12262 1.30 5 2604 1.92
2008/09 Males < 35 38 38995 0.97 31 16257 1.91 113 70616
Males 35–64 55 41937 1.31 24 10714 2.24 123 59483
Females < 35 9 18815 0.48 0 4510 0.00 15 27935
Females 35–64 20 13962 1.43 4 2742 1.46 22 18295
NB: person-years do not sum to ‘Observed opioid-dependent people’ in 2008/09, as some individuals entered the risk set during the year.
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intervals do not account for both sources of uncer-
tainty, estimates are susceptible to over-interpretation.
(v) Imprecise estimates: if the event is relatively rare (e.g.
fDRP) and uncertainty is appropriately accounted
for, the CrI may be extremelywide, and potentially un-
informative for planning and decision-making. For ex-
ample, we identified d = 15 fDRPs among people who
inject drugs in Bristol, England in 2011. We
accounted for uncertainty both in d and our estimate
of the relevant fDRP rate in a Bayesian statistical
framework, but subsequently the CrI around the prev-
alence estimate was very wide: 0.9% (95%
CrI = 0.4–1.6%) [23].
CASE STUDY DATA
We provide a case study of estimation of the number of
opioid-dependent people aged 15–64 in England in the fi-
nancial year 2008/09. We focus on 2008/09 because a
large fully linked data set was available through the Drug
DataWarehouse (DDW), and this was the last year of link-
age. The DDW contains anonymized linked data on all
opioid-dependent people in contactwith treatment services
or identified through criminal justice services in England
between April 2005 and March 2009 [46,50]. Critically
for this estimation exercise, all identified cases were linked
to official mortality records. The treatment records include
dates on which each individual started and ceased each
type of treatment, from which we categorized all periods
as ‘on’ or ‘off ’ opioid substitution treatment. This allowed
us to estimate fDRP rates during periods on versus off treat-
ment [24]. One difficulty, however, is that linkage was
based only on initials and dates of birth. It is therefore ex-
pected that some fDRPs occurring within the DDW sample
were missed. For further details of the linkage process and
its limitations, see Pierce [51].
We produce stratified estimates of prevalence by gender,
age group (15–34 and 35–64 years) and by nine
geographical regions. We index group (gender/age/region
combination) by g = 1,…,36. We denote the number of
opioid-dependent people observed in the DDW in
2008/09 in each group by nDDWg and total (unknown)
prevalence in each group by πg. By definition, πg ¼
nDDWg þ nmissg
 
=Pg , where Pg is the total population size
of group g and nmissg is the number of opioid-dependent
people in group g who were not observed in the DDW
cohort.
For the purposes of this case-study analysis, we use a
restricted definition of fDRP. We model only deaths with
underlying cause coded with ICD10 code F11 (‘Mental
and behavioural disorders due to use of opioids’) or F19
(‘Mental and behaviour disorders due to multiple drug
use and use of other psychoactive substances’), in which
at least one opioid was explicitly mentioned on the death
certificate. F11 and F19 are the categories most likely to
relate to long-term dependent drug use. Herein, we will
use the term fDRP to refer to these deaths specifically.
Note that this is a narrower definition than used in our
simpler analysis in Bristol [24] described above (see ‘Im-
precise estimates’ section); therefore, the estimated rates
of fDRPs are not comparable across these analyses.
In 2008/09, there were 181 fDRPs linked to the
176329 opioid-dependent people in the DDW (Table 1).
Following stratification by the 36 groups and also by treat-
ment status (‘on’ versus ‘off ’), therewere zero fDRPs in sev-
eral cells. This presents difficulties for estimation of fDRP
rates by group and treatment status. To address this issue,
we obtained data of the same form for each of the 4 years of
the DDW, allowing us to estimate fDRP rates more pre-
cisely. Summary data for all 4 years are shown in Table 1.
In addition to the DDWdata, we obtained a data extract
from the Office for National Statistics (ONS) specifying all
fDRPs in 2008/09. For each group g, we subtracted the
number of fDRPs linked to DDW individuals, dDDWg ,
from the total number according to the ONS data extract,
dallg , to obtain the number not linked to the DDW cohort:
dmissg ¼ dallg  dDDWg . In total, 273 fDRPs in 2008/09 were
not linked to the DDW sample (Table 1).
For comparison with what follows, we first provide a
crude estimate of the population size based on these data,
using a Bayesian version of a simple ‘mortality multiplier’
[23]. Aggregating across treatment status and group, the
observed fDRP rate in 2008/09 was 1.22 per 1000
person-years. Using the total number of fDRP in
2008/09 (454) as a single benchmark, we arrive at an es-
timate of 372400 (95% CrI = 313900–444100)
opioid-dependent people, or a prevalence of 1.08% (0.91–
1.29%). This simple approach does not, however, allow
for bias in the estimate of the fDRP rate due to imperfect
matching, or for heterogeneity in fDRP rate.
BAYESIAN MORTALITY-BASED
PREVALENCE ESTIMATION
In this section we describe our approach to modelling the
DDW and ONS data together, simultaneously estimating
models for fDRP rates and for prevalence of opioid
dependence.
General modelling approach
The essence of our approach is as follows. We use the DDW
data to estimate fDRP rates among opioid-dependent peo-
ple during periods ‘on’ and ‘off ’ treatment in 2008/09, by
group. We assume that fDRP rates during periods out of
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treatment derived from this sample also apply to the unob-
served opioid-dependent people who are, by definition, not
in treatment. These mortality rates, together with a regres-
sion model for prevalence, determine our estimates of each
nmissg or, equivalently, of prevalence. Ourmodel also incorpo-
rates a correction for incomplete matching of DDWrecords
to mortality records.
We take a Bayesian approach to estimation using Mar-
kov chain Monte Carlo (MCMC) simulation, because this
enables the computational flexibility required to estimate
all parameters simultaneously. The key difference between
a Bayesian and frequentist approach is the specification of
prior beliefs on parameters being estimated. ‘Uninforma-
tive’ prior distributions lead to parameter estimates that
are driven by the observed data, and would correspond to
results obtained from a frequentist approach if it were pos-
sible to compute it. We use uninformative prior distribu-
tions wherever possible (for more details see the ‘Model
for fDRP rate among opioid-dependent people’ section).
We present an overview of the model in sections ‘Model
for fDRP rate among opioid-dependent people’ and ‘Model
for fDRPs not linked to the DDWdata’. Full details are pro-
vided in the Supporting information, Appendix B.
WinBUGS [52] code used to fit the model is presented in
Supporting information, Appendix C.
Model for fDRP rate among opioid-dependent people
We fitted mixed-effect Poisson regression models to ob-
served fDRPs in the DDW, with person-years at risk as off-
sets. Although the prevalence estimation requires only
estimates of rates during periods out of treatment in
2008/09, we modelled all 4 years of mortality data and
deaths during periods on as well as off treatment. Our mo-
tivation was to borrow strength through some sharing of
parameters, given the sparse mortality data.
The regression model included the following explana-
tory variables: region, gender, age group, treatment status
and year. As year was included as a covariate, the model
allowed for changes in fDRP rates over time. Region was
modelled as a random effect due to small counts. We used
the deviance information criterion (DIC) to explore sup-
port for inclusion of interactions between these explana-
tory variables. Lower values of the DIC indicate a better
fit after penalizing for model complexity [53]. The
DIC supported inclusion of gender × age group,
treatment × age and year × treatment interaction terms,
which were therefore included in the primary analysis. Al-
though there is substantive rationale for the first two of
these, we questioned the plausibility of ‘treatment effects’
on mortality changing considerably over a 4-year period.
In a sensitivity analysis, we therefore explored the impact
of excluding the year × treatment interaction term.
An additional offset ‘pmatch’was included in the regres-
sion model, representing the probability that any fDRP
among the DDW sample was correctly identified through
linkage. This parameter was the only variable assigned
an informative prior distribution in our Bayesian analysis:
this was necessary, as it would be impossible to estimate
this from the data. We assumed that between 74 and
84% of DDW deaths were correctly matched to ONS re-
cords. This was based on examining DDWdata on a cohort
of individuals identified in treatment records as ‘discharged
as dead’ and checking the proportion of these that were
correctly identified by the linkage process. Inclusion of
‘pmatch’ in the model means that estimated fDRP rates
are corrected for imperfect matching to ONS records. Oth-
erwise, rates would be underestimated, subsequently lead-
ing to over-estimates of prevalence. To demonstrate the
impact of the adjustment for imperfect linkage, we also pro-
vide results from an analysis with ‘pmatch’ set to 1.
Estimated ‘off treatment’ fDRP rates in each group are
displayed in Fig. 1.
Model for fDRPs not linked to the DDWdata
We assume Poisson distributions for the number of fDRPs
not linked to the DDW in each group,dmissg . We assume that
the unobserved opioid-dependent people (nmissg ) had a mor-
tality rate equal to the ‘off treatment’mortality rate for the
relevant group, estimated from the model above. We added
an additional term to the expected mean of each dmissg to ac-
count for the proportion, 1-pmatch, of fDRPs occurring
within the DDW sample that were missed by the linkage
process.
Model for prevalence of opioid dependence
Finally, we specified a regression model for the prevalence
of opioid dependence in each group. We assumed a linear
model for logit-transformed prevalence, with age, gender
and region effects. We also included age × gender,
gender × region and age × region interaction terms.
Region-specific intercept terms were unconstrained, while
interactions involving region were modelled as random
effects.
A schematic diagram showing the relationships be-
tween the data sources and parameters is provided in Fig. 2.
Addressing the limitations of the multiplier method
Our approach addresses each of the difficulties described
with traditional multiplier approaches in the ‘Limitations
of traditional multiplier methods’ section.
(i) Bias due to borrowing multipliers across settings: we
minimize potential bias in estimates of fDRP rates by
estimating these from contemporaneous data in
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England. The DDW sample is very large, and can be
expected to include a wide range of opioid-dependent
people and observation periods on and off treatment.
We also allow for an anticipated slight downward bias
in estimated fDRP rates from DDW data, due to
imperfect linkage to mortality records (see the ‘Model
for fDRP rate among opioid-dependent people’
section).
(ii) Failure to account for heterogeneity in the multiplier: a
key feature of our analysis is that we recognize that
opioid-dependent people not observed in the DDW
were, by definition, not in treatment, as the DDW in-
cludes all contact with treatment services. As such,
the mortality rates that we apply to the unobserved
fDRPs to estimate prevalence [after allowing for some
misclassification, as described in (i)] are estimated
rates during periods out of treatment: substantially
higher than rates during treatment [24]. Failure to
account for this would lead to a potentially large
over-estimation of prevalence. Further, we allow for
heterogeneity in fDRP rates by gender, age group
and region.
(iii) Inappropriate case definitions: our restricted definition of
fDRP limits the possibility of the ‘benchmark’ number
of deaths including individuals outside the target pop-
ulation. We use a consistent definition of fDRP across
both parts of the model.
(iv) Failure to adequately account for uncertainty: we use an
MCMC simulations-based estimation approach, in
which each source of sampling uncertainty is auto-
matically propagated to the final prevalence esti-
mates, providing appropriate 95% CrIs.
Figure 1 Estimated fatal drug-related poisoning (fDRP) rates* during periods out of treatment, with 95% credible intervals. *Using our restricted
definition for modelling purposes: see Case study data section
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(v) Imprecise estimates: direct linkage of a large sample of
opioid-dependent people to mortality records
enabled us to specifically estimate the undercount
of the DDW, which we then (essentially) added to
the total observed. This approach substantially re-
duces uncertainty in our final estimates, and is jus-
tifiable given that it is known with certainty that
there are at least as many opioid-dependent people
as observed.
CASE STUDY RESULTS
In total, we estimated there were 106700 (95%
CrI = 78200–147900) ‘unobserved’ opioid-dependent
people in England in 2008/09. This corresponds to an esti-
mated total number of opioid-dependent people of 283100
(95% CrI = 254600–324200), or a prevalence of 0.82%
(0.74–0.94%) among 15–64-year-olds in England. We
note that the total number of opioid-dependent people in
treatment during 2008/09 was 151600 (data from the
DDW: not shown); therefore, our results imply that the to-
tal proportion in treatment at some point during the year
was 46% (41–51%).
Prevalence estimates by gender, age group and region
are shown in Fig. 3. Despite the sparse mortality data by re-
gion, we see that regional differences in prevalence can be
estimated. Across regions, overall prevalence estimates
ranged from 0.53% (0.43–0.67%) in the South East to
1.17% (1.00–1.46%) in the NorthWest. Group-specific es-
timates ranged from 0.15% (0.11–0.20%) in older females
in South East England to 2.51% (1.98–3.35%) in younger
men in the West Midlands.
Estimated patterns by age group and gender were as ex-
pected, with prevalence being estimated to be lower in
older and female populations. There was evidence for mod-
erate variation in the age effect across regions [standard
deviation (SD) of random effects = 0.36, 95%
CrI = 0.18–0.78]: the difference in prevalence by age
group is estimated to be smallest in London and
greatest in the North East. Regional variation in gender ef-
fects on prevalence was smaller (SD = 0.07, 95% CrI =
0.00–0.28).
A sensitivity analysis in which we excluded the
year × treatment interaction term from the mortality
model provided higher estimates of fDRP rates in the un-
treated group in 2008/09, which resulted in a somewhat
lower overall prevalence estimate of 0.78% (0.72–0.87%)
or n = 267300 (245900–298100).
The impact of the adjustment for matching is consider-
able: setting the parameter ‘pmatch’ to 1 (in the primary
model) produced a higher overall prevalence estimate of
0.96% (0.86–1.09%) or n=328800 (296200–373900).
For comparisonwith our estimates, in Fig. 3we also dis-
play the official estimates of the prevalence of opioid depen-
dence in England in 2008/09, based on capture–recapture
estimation [40] (see Discussion).
Figure 2 Schematic diagram showing the relationships between data sources (rectangles) and parameters (ellipses). This is a simplification of the full
model, which also incorporates gender, age group and region effects. Dashed lines with blue shading indicate the correction for imperfect matching of
Drug Data Warehouse (DDW) records to the Office of National Statistics (ONS) mortality register. The parameter ‘pmatch’ is given an
informative prior distribution (see text). Orange shading highlights the key parameter(s) of interest to be estimated, i.e. prevalence of opioid
dependence (π). fDRP =fatal drug-related poisoning [Colour figure can be viewed at wileyonlinelibrary.com]
Prevalence estimation using drug-related mortality data 7
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
DISCUSSION
Main findings
We have described an alternative prevalence estimation
method that utilizes linkage between drug treatment or
other records and mortality registers, addresses the main
limitations of traditional ‘multipliers’ and can be used
when suitable information and data sources for capture–
recapture analysis are unavailable.
Our Bayesian modelling approach involves simulta-
neously fitting two regressions—for mortality rates and
prevalence—allowing for systematic differences in both
factors by gender, age group and region, as well as depen-
dence of fDRP rates on opioid substitution treatment status.
The method also allows us to incorporate information on
misclassification, so that undercounts of deaths in the ob-
served population can be accounted for. The impact of these
factors is demonstrated in our case study where, in a crude
analysis ignoring both of these factors, prevalence was esti-
mated as 1.08%, compared with 0.96% in an analysis ac-
counting for heterogeneity in fDRP rate and prevalence
but not for imperfectmatching, and0.82% inour (primary)
analysis accounting for both factors.
Limitations
We recognize, however, a number of potential limitations
with our approach. First, the method relies upon a rich
data set that can provide contemporaneous estimates of
mortality rates, so that we avoid the rarely justifiable
Figure 3 Estimated prevalence (with 95% credible intervals, CrIs) of opioid dependence in England in 2008/09, by gender, age group and geograph-
ical region. For comparison, estimates from Hay et al. [40] with 95% confidence intervals (CI) are shown in blue [Colour figure can be viewed at
wileyonlinelibrary.com]
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assumption that a ‘multiplier’ from another location or
time is applicable to our target population. In our case
study, we made use of the DDW cohort, which linked all
people reported to be in opioid substitution treatment,
and other administrative data sources that assessed opioid
dependence, with the national mortality register
[24,46,54]. Clearly, establishing the mechanisms and per-
missions for such linkage requires investment. However,
this investment is essential for understanding andmonitor-
ing drug-related mortality. Historically, linked drug treat-
ment and mortality data were rare. However, linked
health data are becoming much more common and cen-
tral to epidemiology amongmultiple fields, including addic-
tion. For example, there were 124 mortality cohort studies
in a recent systematic review, most of which began during
the last 10 years [55]. Our method offers further
motivation for collecting data on drug-related mortality,
which we also note is a comparatively small step if data
on people entering drug treatment are already being
collected [48,49,56].
Secondly, to minimize the possibility of the deaths
modelled being outside the target population (i.e. deaths
in non-opioid-dependent people), we narrowed the defini-
tion of ‘fDRP’ for modelling purposes to F11 and F19 codes
with opioids specified on the death certificate. The draw-
back of this was that the number of deaths to be modelled
was relatively small, reducing statistical power. As a result,
in this case study we were unable to estimate prevalence at
lower geographical levels. This might be feasible if a
broader working definition of fDRP could be used: this
would require more information on the probable propor-
tion of deaths by ICD10 code occurring in the target popu-
lation. Notably the inclusion of random effects in themodel
allows for ‘borrowing of strength’ across subgroups of the
population.
Thirdly, our estimates are dependent upon one main
assumption: that, within each group g, fDRP rates among
unobserved people with opioid disorders are equal to
rates among those observed in the DDW sample during
periods out of treatment. We believe this is justifiable for
older opioid-dependent people in the United Kingdom
(and many other developed countries), as most people
are likely to enter drug treatment at some point [57].
Further, the DDW sample includes some individuals
who were not in treatment during the 4-year sampling
period [46]. Nonetheless, we note that our model aver-
ages the excess risk of overdose out of treatment and does
not specifically account for elevated mortality risk during
the first 4 weeks following treatment cessation [24], nor
for potential differences in fDRP rates by duration of
treatment or pattern of treatment history [58,59]. The
modelling approach could be further developed to allow
for such factors. The key underlying assumption could
also be tested if more data sources were incorporated
within the Bayesian model in a multi-parameter evidence
synthesis framework [60,61].
Finally, our case study results are dependent upon an
informative prior distribution that we derived for
‘pmatch’, the probability that a fDRP among the DDW
sample was correctly identified by linkage. However, this
seems preferable to assuming that linkage is perfect (cor-
responding to setting an extremely strong prior of
pmatch = 1 with certainty). Ideally, we would have
better-quality empirical data on matching to incorporate
into the modelling. We note that imperfect linkage is
also a common difficulty in many capture–recapture ex-
ercises. For example, the annual estimation exercise in
England is similarly based on matching by only initials,
date of birth and gender, and this is not accounted for
in analysis [39].
Other evidence
Capture–recapture is a widely used alternative approach to
prevalence estimation. However, when the dependence
structure across data sources is very complex, and the tar-
get population heterogeneous, we have found capture–
recapture estimates to not be robust: multiple models with
similar fit can produce widely different prevalence esti-
mates (Supporting information, Appendix A, [22]). At a lo-
cal level, careful consideration of the nature of referrals
between services and incorporation of additional informa-
tion may inform choice between competing models [24].
If, however, there is insufficient information to choose be-
tween models, alternative estimation approaches are
needed. Bayesian model-averaging techniques have been
proposed to avoid having to choose between models [21].
However, we do not believe that averaging across compet-
ingmodels producing widely different estimates offers a sci-
entifically justifiable solution.
In our case study analysis we found that our na-
tional and regional estimates of the prevalence of opioid
dependence were similar to published estimates derived
through capture–recapture, but with wider uncertainty
intervals [40]. However, these capture–recapture esti-
mates were based on aggregating results from more
than 150 stratified analyses, unjustified assumptions
and repeated model-fitting using different approaches
until the estimates were deemed credible by the investi-
gators (see Appendix A). Model selection based on cred-
ibility of the results alone is not a valid or replicable
approach [23,24].
Implications
Understanding and monitoring drug-related mortality re-
quires linkage of drug treatment and other administrative
data sets to mortality registers. We demonstrate a method
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that can utilize these linked data to estimate the prevalence
of opioid disorders.
Our method is an initial step to developing a coherent
approach to estimate prevalence of opioid disorders. The
model could be extended to estimate injecting opioid use
and to model changes over time, in addition to incorporat-
ing additional data sources in a multi-parameter evidence
synthesis framework, allowing the consistency of evidence
to be more formally assessed. Estimates of drug-related
harms such as HIVand HCVare reliant upon the assump-
tion that estimates of the prevalence of people who inject
drugs are unbiased [1,62,63]. Our model provides an alter-
native and potentially more justifiable approach than the
current annual capture–recapture exercises in the United
Kingdom, as well as capture–recapture and multiplier
methods used in other countries.
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